Sun, Nov 23, 2014, 6:12 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • spcrash spcrash Mar 28, 2013 8:02 AM Flag

    Cramer at best first he say buy...then he say buy on a pull back.... at 52 weeks high....SELL SELL now!!

     

    Biogen IDEC (BIIB). Other stocks mentioned: Eli Lilly (LLY), Luxottica (LUX), Intuitive Surgical (ISRG)

    Biogen IDEC (BIIB) soared more than 3% after the FDA approved its drug for multiple sclerosis. The stock has given investors a 56% gain since Cramer got behind it in January. However, it might still be worth buying because its valuation is inexpensive; BIIB has a multiple of 19 compared to its 18.3% growth rate. BIIB has several successful drugs for MS, including Avonex, which BIIB is improving to make it longer-lasting. Tecfidera is the most recently approved MS drug produced by BIIB. Tysabri is its leading treatment. Although this drug has significant side effects, it is preferred by doctors, and the company provides sufficient warnings for most patients at risk of developing adverse effects. The company is developing two drugs for hemophilia, expected to be approved by 2014. Cramer would buy BIIB on its next pullback.

    Sentiment: Strong Sell

    This topic is deleted.
 
BIIB
303.55+4.45(+1.49%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.